Literature DB >> 23972655

Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response.

Joyce T Au1, Arjun Mittra, Tae Jin Song, Michael Cavnar, Kyonghwa Jun, Joshua Carson, Sepideh Gholami, Dana Haddad, Sebastien Gaujoux, Sebastien Monette, Paula Ezell, Jedd Wolchok, Yuman Fong.   

Abstract

BACKGROUND: Electroporation uses an electric field to induce pores in the cell membrane that can transfer macromolecules into target cells. Modulation of electrical parameters leads to irreversible electroporation (IRE), which is being developed for tissue ablation. We sought to evaluate whether the application of IRE may induce a lesser electric field in the periphery where reversible electroporation may occur, facilitating gene transfer of a granulocyte macrophage colony-stimulating factor (GM-CSF) plasmid to produce its biologic response.
METHODS: Yorkshire pigs underwent laparotomy, and IRE of the liver was performed during hepatic arterial infusion of 1 or 7 mg of a naked human GM-CSF plasmid. The serum, liver, lymph nodes, and bone marrow were harvested for analysis.
RESULTS: Human GM-CSF level rose from undetectable to 131 pg/mL in the serum at 24 hours after IRE and plasmid infusion. The liver demonstrated an ablation zone surrounded by an immune infiltrate that had greater macrophage intensity than when treated with IRE or plasmid infusion alone. This dominance of macrophages was dose dependent. Distant effects of GM-CSF were found in the bone marrow, where proliferating myeloid cells increased from 14% to 25%.
CONCLUSION: IRE facilitated gene transfer of the GM-CSF plasmid and brought about a local and systemic biologic response. This technique holds potential for tumor eradication and immunotherapy of residual cancer.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23972655      PMCID: PMC4140181          DOI: 10.1016/j.surg.2013.06.005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

1.  Irreversible electroporation of the pancreas in swine: a pilot study.

Authors:  Kevin P Charpentier; Farrah Wolf; Lelia Noble; Brody Winn; Murray Resnick; Damian E Dupuy
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

2.  Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model.

Authors:  Y I Yamashita; M Shimada; H Hasegawa; R Minagawa; T Rikimaru; T Hamatsu; S Tanaka; K Shirabe; J I Miyazaki; K Sugimachi
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

3.  Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.

Authors:  Robert E Neal; Ravi Singh; Heather C Hatcher; Nancy D Kock; Suzy V Torti; Rafael V Davalos
Journal:  Breast Cancer Res Treat       Date:  2010-02-27       Impact factor: 4.872

4.  Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation.

Authors:  Edward W Lee; Christine Chen; Veronica E Prieto; Sarah M Dry; Christopher T Loh; Stephen T Kee
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

5.  Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.

Authors:  Yang Guo; Yue Zhang; Rachel Klein; Grace M Nijm; Alan V Sahakian; Reed A Omary; Guang-Yu Yang; Andrew C Larson
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

6.  Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava.

Authors:  J W Fabre; A Grehan; M Whitehorne; G J Sawyer; X Dong; S Salehi; L Eckley; X Zhang; M Seddon; A M Shah; M Davenport; M Rela
Journal:  Gene Ther       Date:  2007-11-15       Impact factor: 5.250

Review 7.  Application of in vivo electroporation to cancer gene therapy.

Authors:  Takahiko Tamura; Tsuneaki Sakata
Journal:  Curr Gene Ther       Date:  2003-02       Impact factor: 4.391

8.  IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial.

Authors:  Holly M Horton; Peggy A Lalor; Alain P Rolland
Journal:  Methods Mol Biol       Date:  2008

9.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Authors:  Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

10.  Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

Authors:  Miguel-Angel Perales; Jianda Yuan; Sarah Powel; Humilidad F Gallardo; Teresa S Rasalan; Christina Gonzalez; Gregor Manukian; Jian Wang; Yan Zhang; Paul B Chapman; Susan E Krown; Philip O Livingston; Samuel Ejadi; Katherine S Panageas; Manuel E Engelhorn; Stephanie L Terzulli; Alan N Houghton; Jedd D Wolchok
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

View more
  9 in total

1.  Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma.

Authors:  P Marsanic; A Mellano; A Sottile; M De Simone
Journal:  Med Biol Eng Comput       Date:  2017-01-11       Impact factor: 2.602

2.  Percutaneous Ablation of Hepatic Tumors at the Hepatocaval Confluence Using Irreversible Electroporation: A Preliminary Study.

Authors:  Tiankuan Li; Wei Huang; Zhiyuan Wu; Yong Wang; Qingbing Wang; Ziyin Wang; Qin Liu; Jingjing Liu; Shenjie Wang; Xiaoyi Ding; Zhongmin Wang
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

3.  Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy.

Authors:  Jeffry Cutrera; Glenn King; Pamela Jones; Kristin Kicenuik; Elias Gumpel; Xueqing Xia; Shulin Li
Journal:  J Cell Mol Med       Date:  2015-01-27       Impact factor: 5.310

Review 4.  Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies.

Authors:  J A Vogel; E van Veldhuisen; P Agnass; J Crezee; F Dijk; J Verheij; T M van Gulik; M R Meijerink; L G Vroomen; K P van Lienden; M G Besselink
Journal:  PLoS One       Date:  2016-11-21       Impact factor: 3.240

5.  Irreversible electroporation-mediated shRNA knockdown of the HPV18 E6 gene suppresses cervical cancer growth in vitro and in vivo.

Authors:  Zhi-Liang Wang; Wei Zhou; Zheng-Ai Xiong; Teng-Hua Yu; Li-Mei Wu; Cheng-Xiang Li; Cheng-Guo Yao; Yu-Tong Wu; Yuan-Yuan Hua
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

6.  Time-Dependent Impact of Irreversible Electroporation on Pathology and Ablation Size in the Porcine Liver: A 24-Hour Experimental Study.

Authors:  Jantien A Vogel; Eran van Veldhuisen; Lindy K Alles; Olivier R Busch; Frederike Dijk; Thomas M van Gulik; Goos M Huijzer; Marc G Besselink; Krijn P van Lienden; Joanne Verheij
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

Review 7.  Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.

Authors:  Kunpeng Wang; Cong Wang; Hao Jiang; Yaqiong Zhang; Weidong Lin; Jinggang Mo; Chong Jin
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

Review 8.  Effect of pulsed field ablation on solid tumor cells and microenvironment.

Authors:  Yujue Wang; Tian'an Jiang; Liting Xie; Huiyang Wang; Jing Zhao; Lei Xu; Chengyu Fang
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

9.  Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.

Authors:  Brandon J Burbach; Stephen D O'Flanagan; Qi Shao; Katharine M Young; Joseph R Slaughter; Meagan R Rollins; Tami Jo L Street; Victoria E Granger; Lalit K Beura; Samira M Azarin; Satish Ramadhyani; Bruce R Forsyth; John C Bischof; Yoji Shimizu
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 17.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.